LASIK 5 years on…

Article

LASIK is a safe and effective procedure in the correction of myopia five years after surgery, according to a study in the September issue of Ophthalmology.

LASIK is a safe and effective procedure in the correction of myopia five years after surgery, according to a study in the September issue of Ophthalmology.

Naoko Kato and colleagues from the Minamiaoyama Eye Clinic and Keio University, Japan, examined 779 eyes of 402 patients with myopia or myopic astigmatism undergoing LASIK during a five-year period. Changes in uncorrected visual acuity (UCVA), manifest refraction, best-corrected visual acuity (BCVA), intraocular pressure (IOP), corneal thickness, corneal endothelial cell counts and complications were recorded at one week, one, three and six months, and once a year postoperatively.

UCVA improved from 1.27 preoperatively to -0.03 at one day following surgery and -0.08 at one month, with minimal but significant decreases occurring thereafter. Postoperative manifest refraction showed minimal but significant regression after one year. Final BCVA loss was seen in 10 eyes of seven patients. IOP and corneal thickness decreased by 4.0 mmHg and 76.9 µm, respectively as a result of LASIK but remained stable over the follow-up period. Corneal endothelial cell counts demonstrated a significant reduction at five years after surgery, which the researchers believe was likely to be the result of physiological age-related loss. No serious complications were observed.

It was the conclusion of the authors that LASIK is a safe and effective procedure for correcting myopia and myopic astigmatism as long as inclusion and exclusion criteria are respected. However, the researchers did point out that minimal regression is likely to occur over the five-year period.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.